Drug firm Glenmark Pharmaceuticals today said it has received US health regulator's approval to market mupirocin calcium cream, used for treating skin diseases, in the American market.
Glenmark Generics Inc, a subsidiary of Glenmark Generics Ltd, has been granted final abbreviated new drug approval from the United States Food and Drug Administration (USFDA) for mupirocin calcium cream USP 2 per cent, Glenmark Pharmaceuticals said in a statement. "Glenmark will commence shipping immediately," it added.
Glenmark Generics Ltd (GGL) is a subsidiary of Glenmark Pharmaceuticals Ltd and has presence in various global markets including North America. Mupirocin calcium cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area) due to susceptible strains of S aureus and S pyogenes.
According to IMS Health sales data for the twelve-month period ending September 2012, the product generated sales of $56.5 million. Shares of Glenmark Pharmaceuticals were trading at Rs 509 per share on BSE in afternoon trade, down 0.79 per cent from their precious close.